A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Public ClinicalTrials.gov record NCT06764875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Study identification
- NCT ID
- NCT06764875
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 840 participants
Conditions and interventions
Interventions
- 5-fluorouracil Drug
- Capecitabine Drug
- Cisplatin Drug
- Oxaliplatin Drug
- Pembrolizumab Drug
- Rilvegostomig Drug
- Trastuzumab Drug
- Trastuzumab deruxtecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2025
- Primary completion
- Apr 26, 2029
- Completion
- Dec 8, 2030
- Last update posted
- Apr 8, 2026
2025 – 2030
United States locations
- U.S. sites
- 49
- U.S. states
- 27
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99508 | Recruiting |
| Research Site | Phoenix | Arizona | 85054 | Recruiting |
| Research Site | Duarte | California | 91010 | Recruiting |
| Research Site | La Jolla | California | 92037 | Recruiting |
| Research Site | Los Alamitos | California | 90720 | Not yet recruiting |
| Research Site | Los Angeles | California | 90089 | Recruiting |
| Research Site | Santa Monica | California | 90404 | Recruiting |
| Research Site | Solvang | California | 93463 | Recruiting |
| Research Site | Upland | California | 91786 | Recruiting |
| Research Site | Walnut Creek | California | 94598 | Recruiting |
| Research Site | Aurora | Colorado | 80045 | Recruiting |
| Research Site | Newark | Delaware | 19713 | Not yet recruiting |
| Research Site | Jacksonville | Florida | 32207 | Not yet recruiting |
| Research Site | Jacksonville | Florida | 32224 | Recruiting |
| Research Site | Orlando | Florida | 32806 | Recruiting |
| Research Site | Marietta | Georgia | 30060 | Recruiting |
| Research Site | Chicago | Illinois | 60612 | Recruiting |
| Research Site | Chicago | Illinois | 60637 | Not yet recruiting |
| Research Site | Evanston | Illinois | 60201 | Not yet recruiting |
| Research Site | Hinsdale | Illinois | 60521 | Recruiting |
| Research Site | Niles | Illinois | 60714 | Recruiting |
| Research Site | Dyer | Indiana | 46311 | Withdrawn |
| Research Site | Louisville | Kentucky | 40217 | Recruiting |
| Research Site | Silver Spring | Maryland | 20904 | Recruiting |
| Research Site | Boston | Massachusetts | 02114 | Withdrawn |
| Research Site | Boston | Massachusetts | 02118 | Withdrawn |
| Research Site | Detroit | Michigan | 48202 | Not yet recruiting |
| Research Site | Grand Rapids | Michigan | 49503 | Recruiting |
| Research Site | Burnsville | Minnesota | 55337 | Recruiting |
| Research Site | Kansas City | Missouri | 64111 | Withdrawn |
| Research Site | St Louis | Missouri | 63108 | Recruiting |
| Research Site | Omaha | Nebraska | 68198-5885 | Not yet recruiting |
| Research Site | Reno | Nevada | 89502 | Recruiting |
| Research Site | Summit | New Jersey | 07901 | Not yet recruiting |
| Research Site | Santa Fe | New Mexico | 87505 | Recruiting |
| Research Site | New Hyde Park | New York | 11042 | Withdrawn |
| Research Site | New York | New York | 10021 | Recruiting |
| Research Site | Cincinnati | Ohio | 45220 | Recruiting |
| Research Site | Columbus | Ohio | 43210 | Not yet recruiting |
| Research Site | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| Research Site | Knoxville | Tennessee | 37909 | Recruiting |
| Research Site | Nashville | Tennessee | 37232 | Withdrawn |
| Research Site | Dallas | Texas | 75246 | Recruiting |
| Research Site | Webster | Texas | 77598 | Recruiting |
| Research Site | Charlottesville | Virginia | 22908 | Recruiting |
| Research Site | Fairfax | Virginia | 22031 | Withdrawn |
| Research Site | Richmond | Virginia | 23235 | Withdrawn |
| Research Site | Charleston | West Virginia | 25304 | Not yet recruiting |
| Research Site | Madison | Wisconsin | 53792 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 235 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06764875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06764875 live on ClinicalTrials.gov.